Is This Volume Any Indicator Of A New Trend?

NASDAQ:MRKR   Marker Therapeutics, Inc.
MRKR has been a sleeper all year. No major high-volume days and nothing really to write home about. But it managed to pull off a bigger move earlier on. Now that the gap has filled from the drop a few weeks ago & they secured funds, what will this mean for the company's next steps?

"An onslaught of Form 4s showed hand fulls of investors and insiders participating in the recent offering. The company raised the money to fund its Phase 2 trial of MT-401 in acute myeloid leukemia. Marker also plans to develop MultiTAA therapies into clinical trials in other indications and conduct manufacturing activities, among other things.

In addition to this, analysts have also weighed in recently. Cantor Fitzgerald initiated coverage on Marker this month. The firm started MRKR at Overweight and gave a price target of $6."

Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.